Randomized Trialhigh evidence
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
The New England journal of medicine·June 3, 2026·PMID 42234540
Why it mattersPolymyalgia rheumatica often requires prolonged glucocorticoids, leading to significant toxicity. This trial provides high-level evidence that IL-17A inhibition with secukinumab can improve sustained remission and reduce glucocorticoid burden in relapsing disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled